← Back to Clinical Trials
Recruiting NCT06586983

NCT06586983 Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06586983
Status Recruiting
Phase
Sponsor Oslo University Hospital
Condition Hepatitis B
Study Type OBSERVATIONAL
Enrollment 4,500 participants
Start Date 2024-09-04
Primary Completion 2028-09-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Tenofovir Disoproxil Fumarate

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 4,500 participants in total. It began in 2024-09-04 with a primary completion date of 2028-09-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to study models of care for decentralized hepatitis B treatment in Ethiopia. Three different models of decentralized HBV care (standard model, simplified model, test-and-treat model) will be implemented at primary hospitals or health clinics in Ethiopia. Treatment will be given for free to patients who meet the treatment criteria. We will compare clinical outcome, laboratory outcomes and programmatic outcome measures between the 3 models.

Eligibility Criteria

Inclusion Criteria: * Adult (at least 18 years of age) who is HBsAg positive. Exclusion Criteria: * Below 18 years of age. * Negative HBsAg rapid test at screening visit. * Other disease with short life expectancy (disseminated cancer etc.)

Contact & Investigator

Central Contact

Asgeir Johannessen, MD PhD

✉ johannessen.asgeir@gmail.com

📞 +4797983264

Principal Investigator

Asgeir Johannessen, MD PhD

STUDY DIRECTOR

The Hospital of Vestfold

Frequently Asked Questions

Who can join the NCT06586983 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatitis B. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06586983 currently recruiting?

Yes, NCT06586983 is actively recruiting participants. Contact the research team at johannessen.asgeir@gmail.com for enrollment information.

Where is the NCT06586983 trial being conducted?

This trial is being conducted at Addis Ababa, Ethiopia.

Who is sponsoring the NCT06586983 clinical trial?

NCT06586983 is sponsored by Oslo University Hospital. The principal investigator is Asgeir Johannessen, MD PhD at The Hospital of Vestfold. The trial plans to enroll 4,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology